Courier Capital LLC Increases Holdings in Zoetis Inc. (NYSE:ZTS)

Courier Capital LLC raised its position in Zoetis Inc. (NYSE:ZTS) by 80.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,740 shares of the company’s stock after acquiring an additional 1,224 shares during the quarter. Courier Capital LLC’s holdings in Zoetis were worth $535,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ZTS. Vanguard Group Inc. lifted its holdings in Zoetis by 1.0% in the first quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock worth $6,895,235,000 after acquiring an additional 414,605 shares during the last quarter. Bank of New York Mellon Corp lifted its position in shares of Zoetis by 4.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 4,687,902 shares of the company’s stock valued at $812,695,000 after acquiring an additional 178,303 shares during the last quarter. Capital Research Global Investors raised its holdings in Zoetis by 2.3% during the 1st quarter. Capital Research Global Investors now owns 4,050,681 shares of the company’s stock worth $685,416,000 after buying an additional 90,330 shares during the period. Clearbridge Investments LLC lifted its position in shares of Zoetis by 5.8% in the 2nd quarter. Clearbridge Investments LLC now owns 3,044,384 shares of the company’s stock valued at $527,774,000 after acquiring an additional 166,517 shares in the last quarter. Finally, Sarasin & Partners LLP boosted its position in shares of Zoetis by 546.3% in the second quarter. Sarasin & Partners LLP now owns 2,253,590 shares of the company’s stock worth $390,682,000 after buying an additional 1,904,899 shares during the period. 92.80% of the stock is owned by institutional investors and hedge funds.

Zoetis Stock Down 4.0 %

ZTS opened at $181.52 on Friday. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.09 and a current ratio of 3.45. The stock has a fifty day moving average of $189.23 and a 200-day moving average of $177.58. Zoetis Inc. has a fifty-two week low of $144.80 and a fifty-two week high of $201.92. The company has a market capitalization of $82.24 billion, a P/E ratio of 35.52, a P/E/G ratio of 2.94 and a beta of 0.89.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion during the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the previous year, the business earned $1.41 earnings per share. The firm’s quarterly revenue was up 8.3% on a year-over-year basis. On average, equities analysts expect that Zoetis Inc. will post 5.83 EPS for the current year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 3rd. Investors of record on Thursday, October 31st will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, October 31st. This represents a $1.73 annualized dividend and a dividend yield of 0.95%. Zoetis’s dividend payout ratio is 33.86%.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. Stifel Nicolaus upped their target price on Zoetis from $200.00 to $210.00 and gave the stock a “buy” rating in a research report on Wednesday, September 18th. BTIG Research increased their target price on Zoetis from $220.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, August 12th. Piper Sandler boosted their price objective on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. JPMorgan Chase & Co. boosted their price objective on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Argus upgraded shares of Zoetis to a “strong-buy” rating in a research note on Friday, August 9th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.